THINGS YOU SHOULD KNOW ABOUT PETER M. MARKHAM
He is an internationally recognized life sciences industry leader.
Peter has broad scientific expertise in both drug and device development with specific expertise in metabolism, pharmacokinetics, bioanalytical chemistry, and the application of these scientific disciplines to the development of combination products. In 2019, he was the recipient of the Massachusetts Society for Medical Research (MSMR) Business Leader Award, and shares this distinguished honor with a select list of CEOs of large multi-nationals, leading biotechnology companies, and venture funds, including: Genzyme, Biogen, Novartis, Alkermes, Alnylam, CRL, Protein Sciences, MIT, Polaris, and Third Rock ventures.
Prior to co-founding CBSET, Peter served as General Manager of the Worcester/Southbridge division of Charles River Laboratories (CRL) where he had P&L responsibility for its largest multi-disciplinary preclinical business unit, which serviced the Toxicology, Pharmacology, Surgery, Metabolism, Pharmacokinetics, and Bioanalytical Chemistry markets. Prior to CRL, he served as a senior executive and researcher specializing in drug metabolism, pharmacokinetics, and bioanalytical chemistry at companies including: Genzyme Transgenics, Primedica, BioDevelopment Laboratories, and Arthur D. Little Inc. He has authored or co-authored numerous original scientific publications.
He is a regulatory authority.
Peter is known internationally for his expertise in GLP regulatory compliance, setting and implementing corporate regulatory strategy and policies, and leading the development of regulatory strategies for novel technologies. His leadership has been recognized for creating high growth business units, developing novel services, expanding new markets through strategic implementation of and integration of advanced imaging and analytical technologies, and creating high- throughput laboratories.
Through partnering with the FDA, industry, academia, and the international physician community, CBSET has played a key role in advancing medical research, and these efforts have resulted in the clinical introduction and regulatory approval of countless devices and novel therapeutics for an active client base of 2000+ companies internationally.
He is revolutionizing translational research.
Under Peter’s leadership, CBSET has revolutionized how translational research is performed, creating the preeminent center for drug and device development, with a reputation for the highest quality and the ability to conduct complex and novel research programs under strict FDA Good Laboratory Practices (GLPs). “Peter has led CBSET to advance biomedical research by accelerating the evolution of technical and scientific acumen through collaborative projects in the medical device, pharmaceutical, and academic communities,” says Elazer R. Edelman, M.D., Ph.D., Edward J. Poitras Professor in Medical Engineering and Science at MIT, Professor of Medicine at Harvard Medical School, and senior attending cardiologist at Brigham and Women’s Hospital, Boston.
With broad scientific expertise in both drug and device development, Peter co-founded CBSET in 2006. As the company's CEO, he has led the way in establishing CBSET as the undisputed gold standard for preclinical and translational science in the life sciences industry.
